NEWS
Industry News Henry Schein Medical helps automate, streamline patient waiting room process with Yosi Health Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Melville, NY), recently entered into a distribution agreement with Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions. According to Henry Schein, for physicians and patients looking for a streamlined waiting room process, Yosi Health’s patient intake solution, Yosi Intake, can create a contactless waiting room by enabling patients to register at home, helping to improve the patient experience and reduce administrative costs for the practice. Integrated with industry-leading electronic medical record (EMR) and practice management solutions, Yosi Intake and Henry Schein can help deliver a customizable digital solution for scheduling and document management, as well as co-pays and payments. As a result of this partnership, Yosi Health expands Henry Schein Medical’s SolutionsHub to help fulfill the clinical, financial, and operational needs of primary care physicians and specialists, group practices, physicianowned labs, ambulatory surgery centers, and Integrated Delivery Networks (IDNs)/Health Systems.
Tenet to sell urgent care platform to FastMed Tenet Healthcare (Dallas, TX) and FastMed Urgent Care announced they have entered into a definitive agreement under which FastMed will purchase Tenet’s urgent care platform, which is operated under the CareSpot and MedPost brands and managed by Tenet’s United Surgical Partners International (USPI) subsidiary.
FastMed is one of the nation’s largest independent urgent care providers with 104 locations in North Carolina, Arizona and Texas. The transaction will add 87 CareSpot and MedPost centers, increasing patient access to FastMed’s healthcare services in Arizona and Texas, while enabling the company to expand into Florida and California where most of the acquired centers are located. The transaction is expected to be completed in the first quarter of 2021, subject to regulatory approvals and customary closing conditions.
Thermo Fisher Scientific completes acquisition of Phitonex Inc Thermo Fisher Scientific completed the acquisition of Phitonex, Inc. (Durham, NC), a company that has pioneered a spectral dye platform for high-resolution biology applications designed to accelerate research and development in cell therapy, immuno-oncology and immunology research. Phitonex’s product offering will enable Thermo Fisher to offer greater flow cytometry and imaging multiplexing capabilities to meet evolving customer needs in protein and cell analysis research, the company says. The Phiton platform acts as a structure that can maintain a higher number of fluorescent dyes in very specific ways, allowing researchers the ability to analyze single cells in high resolution. This allows researchers to achieve deeper biological insights and more comprehensive data from their cell samples. With the ability to rapidly create a multitude of different dye labels, research teams can significantly increase the number of proteins and cell populations that can be identified in a single flow cytometry experiment. www.repertoiremag.com
•
February 2021
47
